Search Results - Pietro Manuel Ferraro
- Showing 1 - 11 results of 11
-
1
Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report by Luca Calvaruso, Alessandro Naticchia, Pietro Manuel Ferraro, Gisella Vischini, Stefano Costanzi
Published in Case Reports in Nephrology (2019-01-01)Get full text
Article -
2
-
3
Results of a Gene Panel Approach in a Cohort of Patients with Incomplete Distal Renal Tubular Acidosis and Nephrolithiasis by Viola D’Ambrosio, Alessia Azzarà, Eugenio Sangiorgi, Fiorella Gurrieri, Bernhard Hess, Giovanni Gambaro, Pietro Manuel Ferraro
Published in Kidney & Blood Pressure Research (2021-06-01)Get full text
Article -
4
-
5
Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study by Daniela Pugliese, Annalisa Aratari, Stefano Festa, Pietro Manuel Ferraro, Rita Monterubbianesi, Luisa Guidi, Maria Lia Scribano, Claudio Papi, Alessandro Armuzzi
Published in Gastroenterology Research and Practice (2018-01-01)Get full text
Article -
6
Defining metabolic activity of nephrolithiasis – Appropriate evaluation and follow-up of stone formers by Daniel A. Wollin, Adam G. Kaplan, Glenn M. Preminger, Pietro Manuel Ferraro, Antonio Nouvenne, Andrea Tasca, Emanuele Croppi, Giovanni Gambaro, Ita P. Heilberg
Published in Asian Journal of Urology (2018-10-01)Get full text
Article -
7
Radiofrequency Echographic Multi Spectrometry (REMS) Technology for Bone Health Status Evaluation in Kidney Transplant Recipients by Angelo Fassio, Giovanni Adami, Stefano Andreola, Pietro Manuel Ferraro, Paola Pisani, Fiorella Anna Lombardi, Ombretta Viapiana, Maurizio Rossini, Chiara Caletti, Giovanni Gambaro, Matteo Gatti, Davide Gatti
Published in Diagnostics (2024-09-01)Get full text
Article -
8
Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study by Marco Luigetti, Francesca Vitali, Angela Romano, Maria Ausilia Sciarrone, Valeria Guglielmino, Michelangelo Ardito, Andrea Sabino, Serenella Servidei, Geny Piro, Carmine Carbone, Francesca Graziani, Rosa Lillo, Pietro Manuel Ferraro, Guido Primiano
Published in Scientific Reports (2024-08-01)Get full text
Article -
9
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report by Lucia Leccisotti, Francesca Cinti, Gian Pio Sorice, Domenico D’Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Shawn Gugliandolo, Camilla Cocchi, Umberto Capece, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Filippo Crea, Alessandro Giordano, Andrea Giaccari
Published in Cardiovascular Diabetology (2022-09-01)Get full text
Article -
10
Reduced incretin effect precedes diabetes development following duodenopancreatectomy in individuals without diabetes by Gianfranco Di Giuseppe, Laura Soldovieri, Gea Ciccarelli, Pietro Manuel Ferraro, Giuseppe Quero, Francesca Cinti, Umberto Capece, Simona Moffa, Enrico Celestino Nista, Antonio Gasbarrini, Andrea Mari, Sergio Alfieri, Vincenzo Tondolo, Alfredo Pontecorvi, Jens Juul Holst, Andrea Giaccari, Teresa Mezza
Published in The Journal of Clinical Investigation (2024-04-01)Get full text
Article -
11
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes by Francesca Cinti, Lucia Leccisotti, Gian Pio Sorice, Umberto Capece, Domenico D’Amario, Margherita Lorusso, Shawn Gugliandolo, Cassandra Morciano, Andrea Guarneri, Maria Angela Guzzardi, Teresa Mezza, Amedeo Capotosti, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Filippo Crea, Alessandro Giordano, Andrea Giaccari
Published in Cardiovascular Diabetology (2023-12-01)Get full text
Article
